Still 'dwelling in the possibility' - critical update on stem cell therapy for acute on chronic liver failure.

摘要: Stem cells therapy could improve survival in patients with liver failure. Studies on stem cell and related growth factors decompensated cirrhosis has been the forefront but shown heterogenous results. Recent high-quality studies have a lack of efficacy safety. Patients acute-on-chronic failure (ACLF) are unique group high mortality short-term associated rapid onset extrahepatic organ failures. In these patients, there is an urgent need to identify treatments that can function mass, prevent sepsis/organ failure, ameliorate systemic inflammation, increase transplant-free survival. novel treatment ACLF unclear this narrative review, we discuss basics regeneration update current clinical status use for improving our understanding future directions.